Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urology and Nephrology 2021 October;73(5) > Minerva Urology and Nephrology 2021 October;73(5):674-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

EDITORIAL COMMENT   

Minerva Urology and Nephrology 2021 October;73(5):674-6

DOI: 10.23736/S2724-6051.21.04762-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?

Francesco DEL GIUDICE 1, 2 , David D’ANDREA 3, Andrea MARI 4, Francesco SORIA 5, Wojciech KRAJEWSKI 6, Marco MOSCHINI 7, on behalf of the YAU Urothelial Working Group

1 Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy; 2 Department of Urology, Stanford Medical Center, Stanford, CA, USA; 3 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 4 Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy; 5 Division of Urology, Department of Surgical Sciences and Urology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy; 6 Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, University Center of Excellence in Urology, Wroclaw, Poland; 7 Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy



top of page